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Highlights 
 
 Peritoneal and serum concentrations of echinocandins were analyzed in 
surgical patients with suspected candida peritonitis. 
 
 The peritoneal concentrations obtained for the three candins in the 
present study ranged from 0.21 to 0.46 μg/mL for caspofungin, 0.68 to 
0.88 μg/mL for micafungin and to 0.66 to 1.82 μg/mL for anidulafungin, 
and most concentrations were below 1 μg/mL. 
 
 The levels of echinocandins that are achieved in the peritoneum are 
below the concentration of resistant mutant selection published by other 
authors. 
 
 These data warn about mutant selection in patients on prolonged 
treatment with echinocandins and suboptimal control of the abdominal 
infection.  
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Abstract 
Introduction: A possible increase of Candida resistance, specially in C. 
glabrata, has been speculated according to a poor diffusion of echinocandins to 
peritoneal fluid. 
Materials/methods: Peritoneal and serum concentrations of Caspofungin, 
micafungin and anidulafungin were analyzed in surgical patients with suspected 
candida peritonitis. After four days of starting therapy serum and peritoneal 
samples (through peritoneal drainage) were obtained at baseline, 1 h, 6 h, 12h, 
and 24h of drug administration. Micafungin and anidulafungin concentrations 
were determined using high-performance liquid chromatography (HPLC/F), 
whereas caspofungin concentration were stablished by bioassay. 
Results:  A total of 23 critically ill patients with suspected abdominal fungal 
infection who were receiving an echinocandin were prospectively recruited. No 
specific criteria were applied to prescribe one specific echinocadin.  No special 
clinical differences were observed among the 3 groups of patients. All were 
receiving antibiotic therapy, 80% required inotropic drugs and finally fungal 
peritonitis were confirmed in 74% of them. The AUC0_24h (mg*h/L) obtained in 
serum and peritoneal fluid were: 126.84 and 34.38; 98.52 and 18.83; and 66.9 
and 8.78 for anidulafungin, micafungin and caspofungin, respectively.  The 
median concentration in peritoneal fluid ranged from 0.66 to 1.82 μg/ml for 
anidulafungin, 0.68 to 0.88 μg/mL for micafungin and 0.21 to 0.46 μg/ml for 
caspofungin.  
Conclusion: The results show a moderate penetration of echinocandins into 
the peritoneal fluid in these patients. These levels are below the threshold of 
resistance mutant selection published by other authors. It could justify a 
potential risk of resistance in patients with prolonged treatments with 
echinocandins and suboptimal control of the abdominal infection.  
 
Keywords:  
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Introduction 
 The low sensitivity of echinocandins of Candida parapsilosis and the 
development of resistance, especially in Candida glabrata, in patients receiving 
prolonged treatment with echinocandins have recently been the focus of 
diffusion studies on these antifungals at the intra-abdominal level1-5. Different 
pharmacokinetic/pharmacodynamic (PK/PD) studies have recently been 
published for echinocandins6-11, but very few studies have focused on 
candidiasic peritonitis or intra-abdominal fungal infection. None of these studies 
have jointly analyzed the behavior of the three echinocandins in the 
management of abdominal fungal infection. 
 Intra-abdominal candidiasis (IAC) is still poorly understood compared 
with candidemia. To date, data and studies on the efficacy of echinocandins in 
IAC are scarce, and although IAC has a high mortality rate, all current 
international guidelines mainly address candidaemia12. 
 Recent studies indicate that echinocandin resistance rates among C. 
glabrata have increased worldwide13-16. Resistance has been reported to easily 
develop in vitro17-20 and in patients after echinocandin exposure13,21-23, which 
occurs because of the presence of point mutations in hot-spot regions of the 
FKS1 and FKS2 genes13,21,22. These mutations have been associated with 
higher minimal inhibitory concentrations (MICs) and therapeutic failure21,23. 
 The aims of this study was  to analyze PK/PD parameters of the three 
echinocandins (anidulafungin, micafungin, and caspofungin) in serum and 
peritoneal fluid (PF) in post-surgical critically ill patients with proven or 
suspected IAC;  Other aspects related to this series, such as IAC diagnosis 
(including the role of multiplex quantitative real-time PCR and β-D-glucan in 
serum), etiological agents, therapeutic response and prognosis have been 
recently published and complement the information of this work24 
 The study was performed prospectively from 2016 to 2019 at a single 
center, and only patients who provided written consent were included.  
 
Methods 
 This was a prospective PK study in critically ill adult patients who were 
admitted to the Anaesthesiology and Surgical Critical Care Department at 
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Ramon y Cajal Hospital, Madrid, Spain. 
 The inclusion criteria were age ≥18 years, a diagnosis of post-surgical 
nosocomial peritonitis that was refractory to >4 days of antibiotics, and 
undergoing PF drainage. 
 “IAC was defined following the 2013 European Consensus criteria25: 
Yeast detection by direct microscopy examination or growth in culture from 
purulent or necrotic intra-abdominal specimens obtained during surgery or by 
percutaneous aspiration; Candida growth from bile, intra-biliary ducts devices, 
and biopsy of intra-abdominal organs; Candida growth from blood cultures in 
the clinical setting of secondary and tertiary peritonitis in the absence of any 
other pathogen; Candida growth from drainage tubes only if placed less than 24 
h. before the cultures”. 
The following variables were obtained for all patients: age, gender, 
central catheter, parenteral nutrition, ICU, septic shock, APACHE II, intestinal 
perforation or leak, pancreatitis, solid tumor, chemotherapy, diabetes, previus 
chemotherapy, dialysis, Pittet index, Candida score, source of intra-abdominal 
candidiasis, blood cultures, candida isolates, empirical antifungal started and 
30-days mortality. Blood cultures were processed in the Microbiology 
Department at Ramon y Cajal Hospital using the BACTEC FX blood culture 
system (Becton Dickinson Diagnostic Instrument Systems, MD, USA). Fungi 
were identified using mass spectrometry (matrix-assisted laser 
desorption/ionization time-of-flight [MALDI-TOF]; Bruker, Germany). 
 Four days after starting anidulafungin (100 mg/d, first day 200 mg), 
caspofungin (50 mg/d, first day 70 mg), or micafungin (100 mg/d) therapy when 
the patients were at steady state, serum and peritoneal samples (through 
peritoneal drainage) were obtained at the following time points: baseline and at 
1, 6, 12, and 24 h after antifungal administration. The samples were frozen at 
−80°C until analysis. Anidulafungin and micafungin concentrations were 
determined using a validated high-pressure liquid chromatography (HPLC/UV-
F) method. Caspofungin concentrations were established using a bioassay.  
 
Bioassay 
The bioassay involved measuring the biological activity of caspofungin in 
serum samples in a diffusion assay. Preparation of the medium, assay 
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reagents, and the test organism (Candida kefyr ATCC 28838; caspofungin MIC, 
0.06 μg/mL) were previously described26. 
 
High-pressure liquid chromatography assay 
 A new HPLC/UV-F assay was developed using a stepwise gradient 
elution profile. The proposed method enables the specific quantification of 
echinocandin in 150 μL of sample (CS and clinical samples) after a first step of 
protein precipitation and direct injection of resulting supernatant. A HPLC assay 
(Waters 2695 separation module) was developed using a stepwise gradient 
elution profile on a reverse-phase C18, 2.7-μm CortecT3 analytical column (100 
× 4.6 mm) that was maintained at 25°C in conjunction with a Cortecs T3 guard 
column (VanGuard 3.9 × 5 mm). The mobile phase consisted of acetonitrile and 
ammonium acetate (pH 5.5) at a flow rate of 0.6 mL/min. The stepwise gradient 
elution profile was programmed as follows: Solvent A (acetonitrile) was initially 
35% for 1 min and then increased to 70% for 7 min, and finally decreased to 
35% again for the next 3 min. Detection was performed by the specific 
characterization of each compound by its UV profile. Additionally, in-series 
fluorescence detection was also performed (Waters 2475 multi λ Fluorescence 
Detector) because these candins have fluorescence properties. Dual detection 
allows a more specific and sensitive method of quantification.  
The wavelengths of excitation and emission were set at 273 nm and 464 
nm, respectively. The Empower Software (version 3.0, Waters Corporation, MA, 
USA) controlled the HPLC system control, and acquisition and processing of the 
data. For each candin characterization, a comparison of retention times and a 
UV-F profile with authentic standards was performed.  
 
PK evaluation 
Data were processed using Empower Software (version 3.0, Waters 
Chromatography, S.A., Spain). Echinocandin PK analysis was determined using 
a non-compartmental model. All calculations were performed using Microsoft 
Excel® (Microsoft, Redmond, WA, USA) spread sheets, using the PK solver 
add-in program, which has demonstrated equivalence calculating PK/PD 
parameters compared to others specific PK programs. Plots were created with 
GraphPad Prism 7, (La Jolla, CA, USA). The primary PK parameters that were 
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evaluated were the area under the concentration-time curves from 0 to 24 h 
(AUC0–24), maximum concentration (Cmax in mg/L), and minimum concentration 
(Cmin in mg/L).  
 The Ramon y Cajal Hospital institutional review board approved the 
study protocol, and informed consent was obtained from the patients or their 
representatives.  
 
Results 
 Twenty-three critically ill patients with suspected abdominal fungal 
infections were recruited. 
 At our center, no specific criteria are applied to prescribe a specific 
echinocandin. Anidulafungin, caspofungin, or micafungin were prescribed in 11, 
eight, and four patients, respectively, in this study. Table 1 shows the principal 
characteristics of the patients. All patients had recently undergone surgery and 
had a recently implanted abdominal drain. No differences were observed 
among these three groups: all the patients were in critical condition, were 
admitted into the surgical intensive care unit, and more than 80% required 
inotropic drugs. Before antifungal therapy was started, all patients were 
receiving antibiotic therapy for previously confirmed bacterial peritonitis, and 
fungal peritonitis was confirmed in three-quarters of them. Only one patient in 
each of the drug groups required hemodialysis, and no differences in weight or 
serum levels of creatinine, bilirubin, protein, or albumin were observed among 
the three drug groups. All patients were treated with echinocandins at 
conventional doses.   
 After 4 days of therapy (steady state), serum and PF (through peritoneal 
drainage) were collected at baseline, and at 1, 6, 12, and 24 h after 
echinocandin administration. The PK/PD analysis was performed using a non-
compartmental approach and the principal results are shown in Table 2 and 
Figure 1.   
 The AUC0-24h (mg×h/L) that was obtained in serum and PF was highest 
for anidulafungin, followed by micafungin and caspofungin. The ratio of PF-to-
serum (%) was also higher for anidulafungin and the lowest for caspofungin. In 
summary, the results show a moderate penetration of echinocandins into the PF 
in patients with intra-abdominal infections, with a median AUC0-24h for the PF-to-
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plasma ratio of 0.13 to 0.27 at the assumed steady-state. The median 
concentration in PF ranged from 0.66 to 1.82 μg/mL for anidulafungin, 0.68 to 
0.88 μg/mL for micafungin, and 0.21 to 0.46 μg/mL for caspofungin 
 
Discussion 
 The peritoneal concentrations obtained for the three candins in the 
present study ranged from 0.21 to 0.46 μg/mL for caspofungin to 0.66 to 1.82 
μg/mL for anidulafungin, and most concentrations were below 1 μg/mL. This is 
consistent with results published by other authors as a safeguard of efficacy for 
managing patients with IAC because these levels far exceed the MIC90 that 
EUCAST suggests for the usual strains of Candida albicans (0.03 μg/mL), and 
for Candida krusei, C. glabrata, and Candida tropicalis (0.06 μg/mL). However, 
they would be insufficient for the management of Candida parapsilosis (4 
μg/mL)27.  
 Recently, Grau et al. conducted a similar study in which they analyzed 
micafungin PK/PD in surgical patients, and on day 3, they found an AUC0-24h  in 
plasma and PF of 56.5 (52–77.7) mg×h/L and 23.9 (18.8–31.7) mg×h/L, 
respectively, corresponding to a median PF-to-plasma ratio of 0.31. The only 
covariates that were statistically significant and improved the fit of the model 
were total body weight normalized to 70 kg and serum albumin concentration 
normalized to 2.2 g/d, according to the high protein binding of echinocandins1. 
The effect of weight on PK results for echinocandins has also previously been 
demonstrated for caspofungin8 and anidulafungin6, and some studies showed 
that a 25% increase in the anidulafungin dose is recommended in morbidly 
obese patients28. However, in the present study, no morbidly obese patients 
were included, and all the patients in the three groups presented a 
homogeneous profile of weight and albuminemia, which were close to the 
average values mentioned in previous studies. Thus, we believe that the data 
obtained in our study adequately represent the PK of the three candins in this 
type of patient.  
 maxmin0-2440-24h0-24h 27. 
 The levels obtained in PF in our patients were similar to those obtained 
by other authors, and they confirmed a moderate penetration of echinocandins 
into the PF in patients with IAC. Perez-Civantos et al. confirmed anidulafungin 
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levels between 0.7 and 0.9 μg/mL, with an average AUC0-24 of 57.9 mg×h/L,2 
which was similar to the levels obtained by Welte et al. (0.12–0.99 μg×h/mL)3.  
 280-24 Andes et al.7 demonstrated that the AUC/MIC ratio, APACHE II 
score, and history of corticosteroid use were significant independent predictors 
of a favorable response for all Candida species. This study analyzed 493 
patients who were included in two large clinical trials with mycafungin. The 
MIC90 of C. albicans, C. tropicalis, C. glabata, and C. krusei was 0.008 μg/mL, 
0.016 μg/mL, 0.016 μg/mL, and 0.125 μg/mL, respectively, and 1.0 μg/mL for C. 
parapsilosis7. In plasma, fractional target AUC/MIC ratios of 3000 and 285 were 
associated with positive therapeutic outcome in a population PK/PD model of 
patients with invasive candidiasis or candidemia caused by other species 
different to C. parapsilosis and C. parapsilosis, respectively7. 11. 
 Our results confirmed an AUC/3000 ratio in serum of 0.042, 0.032, and 
0.022 for anidulafungin, micafungin, and caspofungin, respectively, which would 
be achieved using the current EUCAST susceptibility cut-off for C. albicans 
(0.03 mg/L), but it would be sub-optimal for C. glabrata, C. krusei, and C. 
tropicalis (0.06 mg/L). The AUC/285 ratio in our study was 0.44, 0.34, and 0.23, 
respectively, which is below the threshold for C. parapsilosis (4 mg/L). Although 
these PK/PD parameters have not been optimized outside serum, low levels 
were obtained in the peritoneum in our study, and other similar studies suggest 
therapeutic this difficulty, especially for C. parapsilosis and C. glabrata.  
 Despite this unfavorable PK/PD data, echinocandins have shown high 
success rates in the treatment of candidemia and other forms of invasive 
candidiasis, including IAC, which are caused by different Candida species such 
as C. parapsilosis. Recently Sganga et al. performed a post hoc analysis to 
determine the efficacy and safety of anidulafungin treatment in patients with IAC 
from five prospective studies 5.  and anidulafungin showed a global response 
rate that was similar to the anidulafungin registrational trial of candidemia, with 
no differences in outcomes in patients with C. albicans compared to C. glabrata 
5312930 
 Recent studies indicated that echinocandin resistance rates among C. 
glabrata clinical isolates have increased worldwide13-16. Rivero et al. exposed in 
vitro susceptible isolates from two patients to an increasing concentration range 
micafungin, and they obtained echinocandin-resistant and FKS mutant colonies 
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after exposure to the lowest micafungin concentration that was considered to 
confer resistance by EUCAST (0.06 mg/L) in less than 48 h of incubation. The 
mutant prevention concentration (MPC), which is defined as the lowest 
concentration that can completely inhibit fungal growth for each isolate after 5 
days of incubation, was documented in this study13, and no significant 
differences were found between the MPC geometric mean after anidulafungin 
or micafungin exposure after 5 days of incubation (2.44 mg/L versus 1.72 
mg/L)13. 33. This finding is significant because the mean peritoneal 
concentrations of the three echinocandins obtained in our study were always 
below these MPCs. Results obtained in the in vitro studies on how 
echinocandin-susceptible C. glabrata strains are able to develop resistance 
after exposure to low echinocandin concentrations supports the fact that C. 
glabrata is able to colonize and survive in certain reservoirs of the human body, 
such as the abdomen29, peritoneum1, gastrointestinal tract30, or mucosal 
surfaces31, because of long-term penetration of echinocandins at lower 
concentrations compared to those that prevent resistance acquisition. 
 This study has several limitations. The sample size was small, and the 
PK variability was high in this population, but the more significant factors that 
were associated with this variability such as weight and serum albumin were 
similar among our patients. PK/PD targets for echinocandins obtained in other 
studies have been developed using plasma data in patients with candidemia, 
and thus, the results could not be directly applied to PF data. We did not 
correlate PK/PD target attainment with clinical response because of the small 
number of patients, with only three-quarters of our patients having a 
microbiologically confirmed fungal infection. Finally, we did not confirm 
resistance to echinocandins in our study, but the study was not designed for 
this purpose, and long-term Candida sp. isolates at the peritoneal level or in 
colonization were not analyzed. 
 In conclusion, our study confirms, as in other similar studies, that there is 
poor diffusion of echinocandins into PF. Anidulafungin has a higher 
concentration and a higher PF-to-plasma ratio compared to micafungin and 
caspofungin, although this was not a differential aspect in clinical response in 
the few studies that focused on the use of echinocandins in IAC. The levels of 
echinocandins that are achieved in the peritoneum are below the concentration 
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of resistant mutant selection that were published by other authors; this was 
clear for C. parapsilosis and for high-risk C. glabrata. These data can explain 
the development of resistance in C. glabrata and warn about mutant selection in 
patients on prolonged treatment with echinocandins and suboptimal control of 
the abdominal infection.  
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Figure 1. Observed echinocandin concentrations in serum and in peritoneal 
fluid. Median concentrations and standar desviation at baseline, 1h, 6h, 12h 
and 24h on day +4 of therapy (anidulafungin: 200 mg on day 1, followed by 
100 mg/d thereafter; caspofungin: 70 mg on day 1, followed by 50 mg/d 
thereafter; micafungin: 100 mg/d (no charge doses)  
 
Figure 1a: anidulafungin 
 
 
 
 
 
 
 
Figure 1b: micafungin 
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Figure 1c: caspofungin  
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Table 1. Characteristics of patients included in the study 
 
 Anidulafungin 
(n: 11) 
Caspofungin 
(n: 8) 
Micafungin 
(n: 4) 
Male, Kg, % 7/11, 63.6% 7/8, 87.5% 3/4, 75% 
APACHE>14, % 9/11, 81.8% 5/8, 62.5% 4/4, 100% 
Inotropic requirements, % 9/11, 81.8% 7/8, 87.5% 4/4, 100% 
Multi-organic failure, % 6/11, 54.5% 3/8, 37.5% 3/4, 75% 
Confirmed bacterial peritonitis, % 11/11, 100% 8/8, 100% 4/4, 100% 
Confirmed fungal peritonitis, % 8/11, 72.7% 6/8, 75% 3/4, 75% 
Candidemia, % 1/11, 9.1% 0 0 
Hemodialysis, % 1/11. 9.1% 1/8, 12.5% 1/4, 25% 
Weight, mean (range) 77.8 (53-98) 78.8 (67-100) 68.2 (45-80) 
Serum bilirubin, mean (mg/dl, range) 1.17 (0.30-4.61) 1.28 (0.31-3.72) 1.12 (0.40-2.31) 
Serum creatinine, mean (mg/dl, range) 1.07 (0.40-1.91) 0.82 (0.51-1.92) 1.20 (0.59-1.94) 
Serum albumin, mean (g/dl, range) 2.24 (1.31-3.74) 2.23 (1.62-.3.71) 2.23 (1.30-3.70) 
Serum protein, mean (g/dl, range) 4.69 (3.62-6.31) 5.05 (3.57-6.34) 4.50 (4.20-5.21) 
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Table 2. Echinocandin pharmacoinetic parameters (mean ± standard 
deviation values)(S: serum; PF: peritoneal fluid) 
 
Antifungal (n)  S   PF Ratio PF/serum (%) 
AND (11) Cmax (mg/L)  7.96±5.40   2.57±2.19 32.3 
 Cmin (mg/L)  3.99±2.73   0.64±0.35 16.1 
 AUC0_24h (mg*h/L)  126.84±78.66   34.38±20.17 27.1 
MCF (4) Cmax (mg/L)  8.45±3.24   0.88±0.69 10.4 
 Cmin (mg/L)  2.04±1.34   0.66±0.47 32.5 
 AUC 0_24 (mg*h/L)  98.52±34.55   18.83±14.05 19.1 
CAS (8) Cmax (mg/L)  5.30±2.66   0.49±0.39 9.2 
 Cmin (mg/L)  1.43±0.73   0.24±0.27 16.9 
 AUC 0_24 (mg*h/L)  66.90±32.71   8.78±7.83 13.1 
AND: anidulafungin; MCF: micafungin; CAS: caspofungin 
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